背景和目的:医学和公众对“长期COVID或COVID后综合征”的认可,以及它对生活质量(QoL)的影响,需要更好地解决疾病负担。目标:我们旨在描述患者出院后3个月和12个月时COVID-19症状和QoL的持续存在。材料和方法:我们进行了一项观察,prospective,以及2021年9月至2022年4月的纵向分析研究。要测量QoL,我们使用了36项简式健康调查(SF-36)的验证版本.结果:我们纳入了68例患者。共有54例(79.4%)患者在三个月时至少报告了一种持续症状,而52(76.4%)在12个月(p=0.804)。一些持续的症状(肌痛,脱发,和咳嗽)在12个月时显著下降(50%vs.30.9%,29.4%vs.13.2%,和23.5%与7.4%;分别p=0.007);相比之下,其他持续性症状(睡眠-觉醒和记忆障碍)更常见(5.9%vs.32.4%和4.4%vs.20.6%;分别p=≤0.001)。关于QoL,随着时间的推移,一些分数出现了统计学上的显著改善,p=≤0.037。十二个月时,呼吸困难,肌痛,和抑郁是与不良身体成分总结(PCS)相关的危险因素,p=≤0.027,而焦虑,抑郁症,疲劳与不良的精神成分总结(MCS)相关,p=≤0.015。结论:由于12个月时持续症状的比例很高,我们建议患者必须继续长期随访以重新分类,诊断,并治疗新的发作症状/疾病。
Background and Objectives: Medical and public recognition of \"long-COVID or post-COVID syndrome\", as well as its impact on the quality of life (QoL), is required to better address the disease burden. Objectives: We aimed to describe the persistence of COVID-19 symptoms and QoL among patients at three and twelve months after their discharge from the hospital. Materials and Methods: We conducted an observational, prospective, and longitudinal analytic study from September 2021 to April 2022. To measure QoL, we used a validated version of the 36-item Short-Form Health Survey (SF-36). Results: We included 68 patients in the study. A total of 54 (79.4%) patients reported at least one persistent symptom at three months vs. 52 (76.4%) at twelve months (p = 0.804). Some persistent symptoms (myalgia,
alopecia, and cough) decreased significantly at twelve months (50% vs. 30.9%, 29.4% vs. 13.2%, and 23.5% vs. 7.4%; respectively, p = 0.007); in contrast, other persistent symptoms (sleep-wake and memory disorders) were more frequent (5.9% vs. 32.4% and 4.4% vs. 20.6%; respectively, p = ≤0.001). Regarding QoL, a statistically significant improvement was observed in some scores over time, p = ≤0.037. At twelve months, dyspnea, myalgia, and depression were risk factors associated with a poor physical component summary (PCS), p = ≤0.027, whereas anxiety, depression, and fatigue were associated with a poor mental component summary (MCS), p = ≤0.015. Conclusion: As the proportion of persistent symptoms at twelve months is high, we suggest that patients must continue under long-term follow up to reclassify, diagnose, and treat new onset symptoms/diseases.